🧬 This partnership focuses on developing T-cell receptor therapies for challenging solid tumors.
🔍 Scientists aim to optimize processes, with IND filing expected next year.
🚀 This advances their mission for effective, efficient therapies targeting hard-to-treat cancers.
Introduction:
This article discusses the expanded collaboration between Xcell Biosciences and AmplifyBio in the field of gene therapy manufacturing, focusing on the recently introduced AVATAR™ Foundry system. The partnership aims to enhance the efficiency and effectiveness of manufacturing engineered T-cell receptor (TCR) therapies for treating solid tumors, which present significant treatment challenges.
- Xcell Biosciences has enhanced its collaboration with AmplifyBio by deploying a new AVATAR™ Foundry system to automate clinical-scale manufacturing workflows.
- The ongoing collaboration centers on improving the manufacturing process for TCR therapies designed to target solid tumors, overcoming obstacles posed by immunosuppressive environments.
- Research efforts have progressed from in vitro to in vivo studies, with an Investigational New Drug (IND) application planned for human trials targeting HPV-positive tumors.
- The AVATAR Foundry system represents a cGMP-compliant platform designed to increase the potency of cell and gene therapies.
- AmplifyBio anticipates that the new system will expedite the commercialization of therapies for solid tumors and optimize T-cell conditioning protocols to enhance therapeutic outcomes.
Conclusion:
The partnership between Xcell Biosciences and AmplifyBio signifies a pivotal advancement in gene therapy manufacturing, particularly for challenging cancers. The implementation of the AVATAR Foundry system demonstrates the commitment to improving therapeutic potency and manufacturing efficiency, with significant implications for future clinical applications and the landscape of cancer treatment.
